RARE - Ultragenyx Pharmaceutical Inc.
IEX Last Trade
43.56
-0.055 -0.126%
Share volume: 19,570
Last Updated: Thu 26 Dec 2024 08:30:05 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$43.62
-0.06
-0.13%
Fundamental analysis
8%
Profitability
0%
Dept financing
21%
Liquidity
53%
Performance
0%
Performance
5 Days
-0.27%
1 Month
-7.62%
3 Months
-20.77%
6 Months
7.94%
1 Year
-8.13%
2 Year
2.05%
Key data
Stock price
$43.56
DAY RANGE
$43.07 - $43.74
52 WEEK RANGE
$38.64 - $60.37
52 WEEK CHANGE
-$9.36
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: Emil D. Kakkis
Region: US
Website: ultragenyx.com
Employees: 1,310
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: ultragenyx.com
Employees: 1,310
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Ultragenyx Pharmaceutical Inc. focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the. treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia.
Recent news